TY  - JOUR
A1  - Schmitt, Jana
A1  - Backes, Christina
A1  - Nourkami-Tutdibi, Nasenien
A1  - Leidinger, Petra
A1  - Deutscher, Stephanie
A1  - Beier, Markus
A1  - Gessler, Manfred
A1  - Graf, Norbert
A1  - Lenhof, Hans-Peter
A1  - Keller, Andreas
A1  - Meese, Eckart
T1  - Treatment-independent miRNA signature in blood of wilms tumor patients
JF  - BMC Genomics
N2  - Background
Blood-born miRNA signatures have recently been reported for various tumor diseases. Here, we compared the miRNA signature in Wilms tumor patients prior and after preoperative chemotherapy according to SIOP protocol 2001.
Results
We did not find a significant difference between miRNA signature of both groups. However both, Wilms tumor patients prior and after chemotherapy showed a miRNA signature different from healthy controls. The signature of Wilms tumor patients prior to chemotherapy showed an accuracy of 97.5% and of patients after chemotherapy an accuracy of 97.0%, each as compared to healthy controls.
Conclusion
Our results provide evidence for a blood-born Wilms tumor miRNA signature largely independent of four weeks preoperative chemotherapy treatment.
KW  - miRNA
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-124034
VL  - 13
IS  - 379
ER  - 
TY  - JOUR
A1  - Schmitt, Jana
A1  - Keller, Andreas
A1  - Nourkami-Tutdibi, Nasenien
A1  - Heisel, Sabrina
A1  - Habel, Nunja
A1  - Leidinger, Petra
A1  - Ludwig, Nicole
A1  - Gessler, Manfred
A1  - Graf, Norbert
A1  - Berthold, Frank
A1  - Lenhof, Hans-Peter
A1  - Meese, Eckart
T1  - Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients
JF  - PLoS ONE
N2  - Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the autoimmune response in patients with neuroblastoma and patients with Wilms tumor representing two different childhood tumors. We were able to differentiate untreated neuroblastoma patients from untreated Wilms tumor patients with an accuracy of 86.8%, a sensitivity of 87.0% and a specificity of 86.7%. The separation of treated neuroblastoma patients from treated Wilms tumor patients' yielded comparable results with an accuracy of 83.8%. We furthermore identified the antigens that contribute most to the differentiation between both tumor types. The analysis of these antigens revealed that neuroblastoma was considerably more immunogenic than Wilms tumor. The reported antigens have not been found to be relevant for comparative analyses between other tumors and controls. In summary, neuroblastoma appears as a highly immunogenic tumor as demonstrated by the extended number of antigens that separate this tumor from Wilms tumor.
KW  - Heparan-sulfate
KW  - N-Myc
KW  - Serum autoantibodies
KW  - Suppressors EXT1
KW  - Neuro-blastoma
KW  - Allelic loss
KW  - Lung-cancer
KW  - Children
KW  - Amplification
KW  - Therapy
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133794
VL  - 6
IS  - 12
ER  -